These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21858532)

  • 1. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
    Xenidis N; Chelis L; Amarantidis K; Chamalidou E; Dimopoulos P; Courcoutsakis N; Tentes A; Chiotis A; Prassopoulos P; Kakolyris S
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):477-84. PubMed ID: 21858532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
    Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
    Song HS; Do YR; Chang HM; Ryu MH; Lee KH; Kim YH; Hong DS; Cho JY; Lee KE; Kim SY
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):763-8. PubMed ID: 18172648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
    De Jesus-Acosta A; Oliver GR; Blackford A; Kinsman K; Flores EI; Wilfong LS; Zheng L; Donehower RC; Cosgrove D; Laheru D; Le DT; Chung K; Diaz LA
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):415-24. PubMed ID: 21800112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
    Middleton G; Silcocks P; Cox T; Valle J; Wadsley J; Propper D; Coxon F; Ross P; Madhusudan S; Roques T; Cunningham D; Falk S; Wadd N; Harrison M; Corrie P; Iveson T; Robinson A; McAdam K; Eatock M; Evans J; Archer C; Hickish T; Garcia-Alonso A; Nicolson M; Steward W; Anthoney A; Greenhalf W; Shaw V; Costello E; Naisbitt D; Rawcliffe C; Nanson G; Neoptolemos J
    Lancet Oncol; 2014 Jul; 15(8):829-40. PubMed ID: 24954781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
    Hubner RA; Worsnop F; Cunningham D; Chau I
    Pancreas; 2013 Apr; 42(3):511-5. PubMed ID: 23462324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
    J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
    J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
    Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
    Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.